Molecular neurotoxicological models of Parkinsonism: focus on genetic manipulation of mice.
暂无分享,去创建一个
[1] L. Seiden,et al. Long-lasting depletions of striatal dopamine and loss of dopamine uptake sites following repeated administration of methamphetamine , 1980, Brain Research.
[2] D. Housman,et al. p53-dependent apoptosis modulates the cytotoxicity of anticancer agents , 1993, Cell.
[3] G. C. Wagner,et al. Methamphetamine-induced neuronal damage: A possible role for free radicals , 1989, Neuropharmacology.
[4] H Ujike,et al. VMAT2 knockout mice: heterozygotes display reduced amphetamine-conditioned reward, enhanced amphetamine locomotion, and enhanced MPTP toxicity. , 1997, Proceedings of the National Academy of Sciences of the United States of America.
[5] L. Sklar,et al. Hydrogen peroxide-induced injury of cells and its prevention by inhibitors of poly(ADP-ribose) polymerase. , 1986, Proceedings of the National Academy of Sciences of the United States of America.
[6] S. O'dell,et al. MK‐801 protection against methamphetamine‐induced striatal dopamine terminal injury is associated with attenuated dopamine overflow , 1992, Synapse.
[7] J. Bennett,et al. Dopamine neurons from transgenic mice with a knockout of the p53 gene resist MPTP neurotoxicity. , 1996, Neurodegeneration : a journal for neurodegenerative disorders, neuroprotection, and neuroregeneration.
[8] C. Marsden,et al. Basal Lipid Peroxidation in Substantia Nigra Is Increased in Parkinson's Disease , 1989, Journal of neurochemistry.
[9] J. Cadet,et al. The intrastriatal 6-hydroxydopamine model of hemiparkinsonism: quantitative receptor autoradiographic evidence of correlation between circling behavior and presynaptic as well as postsynatic nigrostriatal markers in the rat , 1992, Brain Research.
[10] W Slikker,et al. MPTP‐induced oxidative stress and neurotoxicity are age‐dependent: Evidence from measures of reactive oxygen species and striatal dopamine levels , 1994, Synapse.
[11] W. Nicklas,et al. Role for excitatory amino acids in methamphetamine-induced nigrostriatal dopaminergic toxicity. , 1989, Science.
[12] J. Cadet,et al. Melatonin attenuates methamphetamine‐induced toxic effects on dopamine and serotonin terminals in mouse brain , 1998, Synapse.
[13] Scott W. Lowe,et al. p53 is required for radiation-induced apoptosis in mouse thymocytes , 1993, Nature.
[14] S. Appel,et al. Scientific approaches to clinical neurology , 1977 .
[15] R. S. Burns,et al. Intraneuronal generation of a pyridinium metabolite may cause drug-induced parkinsonism , 1984, Nature.
[16] C. Epstein,et al. Rapid Communication: Attenuation of Methamphetamine‐Induced Neurotoxicity in Copper/Zinc Superoxide Dismutase Transgenic Mice , 1994, Journal of neurochemistry.
[17] S. Snyder,et al. Nitric oxide activation of poly(ADP-ribose) synthetase in neurotoxicity. , 1994, Science.
[18] T. Dawson,et al. Role of neuronal nitric oxide in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced dopaminergic neurotoxicity. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[19] K. Chiba,et al. Metabolism of the neurotoxic tertiary amine, MPTP, by brain monoamine oxidase. , 1984, Biochemical and biophysical research communications.
[20] S. O'dell,et al. Excitotoxic striatal lesions protect against subsequent methamphetamine-induced dopamine depletions. , 1994, The Journal of pharmacology and experimental therapeutics.
[21] M. Mattson,et al. Evidence for Synaptic Apoptosis , 1998, Experimental Neurology.
[22] G. Cohen. Monoamine oxidase, hydrogen peroxide, and Parkinson's disease. , 1987, Advances in neurology.
[23] Syed F. Ali,et al. The Neuronal Nitric Oxide Synthase Inhibitor, 7‐Nitroindazole, Protects Against Methamphetamine‐Induced Neurotoxicity In Vivo , 1996, Journal of neurochemistry.
[24] R. DePinho,et al. p53-dependent apoptosis produced by Rb-deficiency in the developing mouse lens , 1994, Nature.
[25] J. Cadet,et al. p53‐Knockout Mice Are Protected Against the Long‐Term Effects of Methamphetamine on Dopaminergic Terminals and Cell Bodies , 1997, Journal of neurochemistry.
[26] D Giulian,et al. Characterization of ameboid microglia isolated from developing mammalian brain , 1986, The Journal of neuroscience : the official journal of the Society for Neuroscience.
[27] Sanford P. Markey,et al. Chronic parkinsonism secondary to intravenous injection of meperidine analogues , 1979, Psychiatry Research.
[28] S. Daniel,et al. Glutathione‐related enzymes in brain in Parkinson's disease , 1994, Annals of neurology.
[29] J. Cadet,et al. Invited Review Free radicals and the pathobiology of brain dopamine systems , 1998, Neurochemistry International.
[30] J. Cadet,et al. Nitric Oxide Is a Mediator of Methamphetamine (METH)‐Induced Neurotoxicity , 1996, Annals of the New York Academy of Sciences.
[31] J. Cadet,et al. Retrograde degeneration of nigrostriatal neurons induced by intrastriatal 6-hydroxydopamine injection in rats , 1991, Brain Research Bulletin.
[32] Y. Agid,et al. Iron and Aluminum Increase in the Substantia Nigra of Patients with Parkinson's Disease: An X‐Ray Microanalysis , 1991, Journal of neurochemistry.
[33] R. Duvoisin,et al. Dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine in mice. , 1984, Science.
[34] I. Kopin. MPTP: an industrial chemical and contaminant of illicit narcotics stimulates a new era in research on Parkinson's disease. , 1987, Environmental health perspectives.
[35] A. Fornace,et al. Induction of Cellular p53 Activity by DNA-Damaging Agents and Growth Arrest , 1993, Molecular and cellular biology.
[36] J. Cadet,et al. Attenuation of 6-hydroxydopamine-induced dopaminergic nigrostriatal lesions in superoxide dismutase transgenic mice , 1998, Neuroscience.
[37] J. Cadet,et al. Regional effects of 6-hydroxydopamine (6-OHDA) on free radical scavengers in rat brain , 1989, Brain Research.
[38] J. Langston,et al. Fate of nigrostriatal neurons in young mature mice given 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine: A neurochemical and morphological reassessment , 1986, Brain Research.
[39] C. Miller,et al. Alzheimer's and Parkinson's disease. Brain levels of glutathione, glutathione disulfide, and vitamin E. , 1991, Molecular and chemical neuropathology.
[40] J. Cadet,et al. Methamphetamine‐Induced Changes in Antioxidant Enzymes and Lipid Peroxidation in Copper/Zinc‐Superoxide Dismutase Transgenic Mice , 1998, Annals of the New York Academy of Sciences.
[41] Ted M. Dawson,et al. Inducible nitric oxide synthase stimulates dopaminergic neurodegeneration in the MPTP model of Parkinson disease , 1999, Nature Medicine.
[42] T. Montine,et al. Enhanced N‐Methyl‐4‐Phenyl‐1,2,3,6‐Tetrahydropyridine Toxicity in Mice Deficient in CuZn‐Superoxide Dismutase or Glutathione Peroxidase , 2000, Journal of neuropathology and experimental neurology.
[43] J. Cardelli. The Abundance of Heavy Elements in Interstellar Gas , 1994, Science.
[44] D. Guastella,et al. Poly(ADP-ribose) polymerase activation mediates 1-methyl-4-phenyl-1, 2,3,6-tetrahydropyridine (MPTP)-induced parkinsonism. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[45] C. Marsden,et al. Indices of oxidative stress and mitochondrial function in individuals with incidental Lewy body disease , 1994, Annals of neurology.
[46] Peter Riederer,et al. Transition Metals, Ferritin, Glutathione, and Ascorbic Acid in Parkinsonian Brains , 1989, Journal of neurochemistry.
[47] P. Mcgeer,et al. Reactive microglia are positive for HLA‐DR in the substantia nigra of Parkinson's and Alzheimer's disease brains , 1988, Neurology.
[48] M. V. Van Woert,et al. Brain peroxidase and catalase in Parkinson disease. , 1975, Archives of neurology.
[49] J. Penney,et al. 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyride Neurotoxicity Is Attenuated in Mice Overexpressing Bcl-2 , 1998, The Journal of Neuroscience.
[50] R. Marttila,et al. Oxygen toxicity protecting enzymes in Parkinson's disease Increase of superoxide dismutase-like activity in the substantia nigra and basal nucleus , 1988, Journal of the Neurological Sciences.
[51] C. Mytilineou,et al. Destruction of sympathetic nerve terminals by 6-hydroxydopamine: protection by 1-phenyl-3-(2-thiazolyl)-2-thiourea, diethyldithiocarbamate, methimazole, cysteamine, ethanol and n-butanol. , 1976, The Journal of pharmacology and experimental therapeutics.
[52] John Calvin Reed,et al. Tumor suppressor p53 is a regulator of bcl-2 and bax gene expression in vitro and in vivo. , 1994, Oncogene.
[53] P. Huang,et al. Resistance of neuronal nitric oxide synthase-deficient mice to methamphetamine-induced dopaminergic neurotoxicity. , 1998, The Journal of pharmacology and experimental therapeutics.
[54] K. Jellinger,et al. Iron and ferritin in substantia nigra in Parkinson's disease. , 1993, Advances in neurology.
[55] S. Kish,et al. Glutathione peroxidase activity in Parkinson's disease brain , 1985, Neuroscience Letters.
[56] D. Murphy,et al. Suppression of hydroxyl radical formation by MAO inhibitors: a novel possible neuroprotective mechanism in dopaminergic neurotoxicity. , 1994, Journal of neural transmission. Supplementum.
[57] M. LaVoie,et al. Dopamine Quinone Formation and Protein Modification Associated with the Striatal Neurotoxicity of Methamphetamine: Evidence against a Role for Extracellular Dopamine , 1999, The Journal of Neuroscience.
[58] J. Langston,et al. Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis. , 1983, Science.
[59] C. Epstein,et al. Autoradiographic evidence for methamphetamine-induced striatal dopaminergic loss in mouse brain: attenuation in CuZn-superoxide dismutase transgenic mice , 1996, Brain Research.
[60] T. Dawson,et al. Mechanisms of nitric oxide-mediated neurotoxicity in primary brain cultures , 1993, The Journal of neuroscience : the official journal of the Society for Neuroscience.
[61] J. Langston,et al. MPTP-induced parkinsonism in human and non-human primates--clinical and experimental aspects. , 1984, Acta neurologica Scandinavica. Supplementum.
[62] G. Uhl,et al. Cocaine reward and MPTP toxicity: alteration by regional variant dopamine transporter overexpression. , 1999, Brain research. Molecular brain research.
[63] Haruhiko Akiyama,et al. Rate of cell death in parkinsonism indicates active neuropathological process , 1988, Annals of neurology.
[64] Cytotoxicity of microglia , 1993 .
[65] A. Kimchi,et al. Wild-type p53 induces apoptosis of myeloid leukaemic cells that is inhibited by interleukin-6 , 1991, Nature.
[66] S. Chakraborti,et al. Oxidant, mitochondria and calcium: an overview. , 1999, Cellular signalling.
[67] C. Epstein,et al. Transgenic mice with increased Cu/Zn-superoxide dismutase activity are resistant to N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity , 1992, The Journal of neuroscience : the official journal of the Society for Neuroscience.
[68] D. Sulzer,et al. Methamphetamine neurotoxicity involves vacuolation of endocytic organelles and dopamine-dependent intracellular oxidative stress , 1994, The Journal of neuroscience : the official journal of the Society for Neuroscience.
[69] N. Sone,et al. Effects of 1‐Methyl‐4‐Phenyl‐1,2,3,6‐Tetrahydropyridine and 1‐Methyl‐4‐Phenylpyridinium Ion on Activities of the Enzymes in the Electron Transport System in Mouse Brain , 1987, Journal of neurochemistry.
[70] H. Hermeking,et al. Mediation of c-Myc-induced apoptosis by p53. , 1994, Science.
[71] S Fahn,et al. Monoamines in the human neostriatum: topographic distribution in normals and in Parkinson's disease and their role in akinesia, rigidity, chorea, and tremor. , 1971, Journal of the neurological sciences.
[72] C. Marsden,et al. A Selective Increase in Particulate Superoxide Dismutase Activity in Parkinsonian Substantia Nigra , 1989, Journal of neurochemistry.
[73] G. Breese,et al. Effect of 6-hydroxydopamine on brain norepinephrine and dopamine evidence for selective degeneration of catecholamine neurons. , 1970, The Journal of pharmacology and experimental therapeutics.
[74] C. Marsden,et al. Alterations in levels of iron, ferritin, and other trace metals in neurodegenerative diseases affecting the basal ganglia , 1992 .
[75] M. Fritsche,et al. Induction of nuclear accumulation of the tumor-suppressor protein p53 by DNA-damaging agents. , 1993, Oncogene.
[76] E. Melamed,et al. Transgenic mice expressing human Bcl-2 in their neurons are resistant to 6-hydroxydopamine and 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine neurotoxicity. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[77] S. Fahn,et al. The oxidant stress hypothesis in Parkinson's disease: Evidence supporting it , 1992, Annals of neurology.
[78] D. Hinshaw,et al. Oxidant injury of cells. DNA strand-breaks activate polyadenosine diphosphate-ribose polymerase and lead to depletion of nicotinamide adenine dinucleotide. , 1986, The Journal of clinical investigation.
[79] M. Zigmond,et al. Estimating Hydroxyl Radical Content in Rat Brain Using Systemic and Intraventricular Salicylate: Impact of Methamphetamine , 1995, Journal of neurochemistry.
[80] N. Hay,et al. Myc-mediated apoptosis requires wild-type p53 in a manner independent of cell cycle arrest and the ability of p53 to induce p21waf1/cip1. , 1994, Genes & development.
[81] S. Snyder,et al. Parkinsonism-inducing neurotoxin, N-methyl-4-phenyl-1,2,3,6 -tetrahydropyridine: uptake of the metabolite N-methyl-4-phenylpyridine by dopamine neurons explains selective toxicity. , 1985, Proceedings of the National Academy of Sciences of the United States of America.
[82] A. Schapira,et al. Evidence for mitochondrial dysfunction in Parkinson's disease—a critical appraisal , 2004, Movement disorders : official journal of the Movement Disorder Society.
[83] J. Cadet,et al. Methamphetamine induces apoptosis in immortalized neural cells: Protection by the Proto‐Oncogene, bcl‐2 , 1997, Synapse.
[84] R. Duvoisin,et al. Dopaminergic toxicity of rotenone and the 1-methyl-4-phenylpyridinium ion after their stereotaxic administration to rats: Implication for the mechanism of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine toxicity , 1985, Neuroscience Letters.
[85] M. Lovett,et al. Transgenic mice with increased Cu/Zn-superoxide dismutase activity: animal model of dosage effects in Down syndrome. , 1987, Proceedings of the National Academy of Sciences of the United States of America.
[86] J. Cadet,et al. Methamphetamine administration causes overexpression of nNOS in the mouse striatum , 1999, Brain Research.
[87] G. Cohen,et al. The generation of hydrogen peroxide, superoxide radical, and hydroxyl radical by 6-hydroxydopamine, dialuric acid, and related cytotoxic agents. , 1974, The Journal of biological chemistry.
[88] Syed F. Ali,et al. Effects of 7‐Nitroindazole, an NOS Inhibitor on Methamphetamine‐Induced Dopaminergic and Serotonergic Neurotoxicity in Mice a , 1998, Annals of the New York Academy of Sciences.
[89] M. Beal,et al. Manganese Superoxide Dismutase Overexpression Attenuates MPTP Toxicity , 1998, Neurobiology of Disease.
[90] S. Korsmeyer,et al. Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programed cell death , 1993, Cell.
[91] C. Marsden,et al. Mitochondrial Complex I Deficiency in Parkinson's Disease , 1990, Lancet.
[92] K. Jellinger,et al. Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations. , 1973, Journal of the neurological sciences.
[93] C. Purdie,et al. Thymocyte apoptosis induced by p53-dependent and independent pathways , 1993, Nature.
[94] B. Vogelstein,et al. Participation of p53 protein in the cellular response to DNA damage. , 1991, Cancer research.
[95] J. Cadet,et al. Long-term behavioral and biochemical effects of 6-hydroxydopamine injections in rat caudate-putamen , 1991, Brain Research Bulletin.
[96] B. Yamamoto,et al. Methamphetamine‐induced neurotoxicity: Roles for glutamate and dopamine efflux , 1994, Synapse.